SCHEMBL21903578

SCHEMBL21903578

CC(C)(C)OC(=O)N1CCCC(n2nc(C(=O)O)c3c(N)nccc32)C1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BTK Q06187 14/20 0.46
SRC P12931 4/20 0.45
EGFR P00533 3/20 0.45
PIK3CD O00329 2/20 0.43
PIK3CA P42336 2/20 0.43
PIK3CB P42338 2/20 0.43
PIK3CG P48736 2/20 0.43
PIK3R2 O00459 1/20 0.43
PIK3R5 Q8WYR1 1/20 0.43
PIK3R3 Q92569 1/20 0.43
ABL1 P00519 1/20 0.41
HCK P08631 1/20 0.41
KDR P35968 1/20 0.41
MTOR P42345 1/20 0.41
EPHB4 P54760 1/20 0.41
PRKDC P78527 1/20 0.41
PI4KB Q9UBF8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20645478 1.00 BTK (0.46) BTKSRCEGFRPIK3CDPIK3CA
SCHEMBL31684306 0.93 BTK (0.45) BTKSRCEGFRPIK3CDPIK3CA
SCHEMBL20645511 0.93 BTK (0.45) BTKSRCEGFRPIK3CDPIK3CA
SCHEMBL22009457 0.91 BTK (0.45) BTKSRCEGFRPIK3CDPIK3CA
SCHEMBL21965625 0.91 BTK (0.45) BTKSRCEGFRPIK3CDPIK3CA
SCHEMBL31684335 0.91 BTK (0.45) BTKSRCEGFRPIK3CDPIK3CA
SCHEMBL22009062 0.88 JAK2 (0.48) BTKSRCEGFRPIK3CDPIK3CA
SCHEMBL21903722 0.88 JAK2 (0.48) BTKSRCEGFRPIK3CDPIK3CA
SCHEMBL6274546 0.88 EGFR (0.48) BTKSRCEGFRPIK3CDPIK3CA
SCHEMBL21579420 0.88 EGFR (0.48) BTKSRCEGFRPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3653626-B1 NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME DAEWOONG PHARMACEUTICAL CO LTD (KR) 2025-09-17 EP disclosed
US-11180496-B2 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2021-11-23 US disclosed
EP-3653626-A1 NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Daewoong Pharmaceutical Co., Ltd. (KR) 2020-05-20 EP disclosed
US-20200140432-A1 NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2020-05-07 US disclosed
CN-110914266-A Novel 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same 株式会社大熊制药 2020-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11180496-B2 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same PDCD11, DPYD, G6PC1 BTK 1236/4885SRC 2239/4885EGFR 4597/4885
US-20200140432-A1 NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME PDCD11, G6PC1, PPM1D BTK 1744/4885SRC 2768/4885EGFR 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.